Table 3

Relationship between mRNA MYC status and the standard clinical, pathological, and biological factors

Total population (%)Normal MYC mRNAOverexpressed MYC mRNAa
No. of patients (%)No. of patients (%)Pb
Total134 (100.0)105 (78.4)29 (21.6)
AgeNS
 H5041 (30.6)31 (29.5)10 (34.5)
 >5093 (69.4)74 (70.5)19 (65.5)
Menopausal statusNS
 Premenopausal47 (35.1)33 (31.4)14 (48.3)
 Postmenopausal87 (64.9)72 (68.6)15 (51.7)
Histological gradec<0.05
 I18 (14.4)17 (17.2)1 (3.8)
 II60 (48.0)50 (50.5)10 (38.5)
 III47 (37.6)32 (32.3)15 (57.7)
Lymph node statusNS
 Node-negative50 (37.3)40 (38.1)10 (34.5)
 Node-positive84 (62.7)65 (61.9)19 (65.5)
Estrogen receptor statusNS
 +(≥10 fm/mg)89 (66.4)72 (68.6)17 (58.6)
 −(<10 fm/mg)45 (33.6)33 (31.4)12 (41.4)
Progesterone receptor statusNS
 +(≥10 fm/mg)79 (59.0)72 (59.1)17 (58.6)
 −(<10 fm/mg)55 (41.0)43 (40.9)12 (41.4)
Macroscopic tumor sized<0.01
 H30 mm93 (73.2)81 (80.2)12 (46.2)
 >30 mm34 (26.8)20 (19.8)14 (53.8)
RelapsesNS
 +48 (35.8)41 (39.1)7 (24.1)
 −86 (64.2)64 (60.9)22 (75.9)
  • a RMYC value ≥3.

  • b χ2 test. NS, not significant.

  • c Scarff Bloom Richardson classification. Information is available for 125 patients.

  • d Information is available for 127 patients.